Novel insights on [1,2]oxazolo[5,4-e]isoindoles on multidrug resistant acute myeloid leukemia cell line

Drug Dev Res. 2022 Sep;83(6):1331-1341. doi: 10.1002/ddr.21962. Epub 2022 Jun 24.

Abstract

A series of [1,2]oxazolo[5,4-e]isoindole derivatives was evaluated against HL-60 cell line and its multidrug resistance (MDR) variant, HL-60R, resistant to doxorubicin and to other P-gp substrates by overexpressing the efflux pump. They displayed antiproliferative activities, with IC50 values ranging from 0.02 to 5.5 µM. In particular, the newly synthesized compound 4k produced synergistic effects in terms of cell growth inhibition and cell death induction either in combination with a Vinca alkaloid, Vinblastine, and a Taxane, Paclitaxel in HL-60R cells. The study of the mechanism of action indicated that all compounds showed antimitotic activity through inhibition of tubulin polymerization. Thus, [1,2]oxazoles could represent a valuable tool to overcome MDR mechanism, confirming the potential use of this class of compounds.

Keywords: [1,2]oxazolo[5,4-e]isoindoles; antimitotic agents; multidrug resistance.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents* / chemistry
  • Antineoplastic Agents* / pharmacology
  • Cell Line
  • Drug Resistance, Multiple
  • Drug Resistance, Neoplasm
  • Humans
  • Isoindoles / pharmacology
  • Leukemia, Myeloid, Acute* / drug therapy

Substances

  • Antineoplastic Agents
  • Isoindoles